Michael Kahn, PhD

home / authors / michael-kahn-phd

Articles

CBP/β-catenin Antagonists: A Safe and Novel Approach for Skin Rejuvenation and Aging

CBP/β-catenin Antagonists: A Safe and Novel Approach for Skin Rejuvenation and Aging

Michael Kahn, PhD;Paul Scott Premo
January 5th 2024

Take a look at this overview of the top 5 considerations to show how CBP/β-catenin antagonists can be utilized for skin rejuvenation and anti-aging by enhancing Wnt/p300/β-catenin transcription.

Latest Updated Articles

2 KOLs are featured in this series.
Published: September 19th 2024 | Updated: September 26th 2024
Final Thoughts: The Importance of Comparative Studies in AD
Optimizing Laser Therapy for Vascular Anomalies: Why Early Multidisciplinary Care Matters
Published: March 11th 2025 | Updated: April 1st 2025
Optimizing Laser Therapy for Vascular Anomalies: Why Early Multidisciplinary Care Matters
Apoptosis-Based Skin Cancer Treatment Shows Promise
Published: March 15th 2025 | Updated: April 1st 2025
Apoptosis-Based Skin Cancer Treatment Shows Promise
Tattoo Ink Risks, MultiFrax Laser, and the Impact of GLP-1 Medications on Skin Health
Published: March 7th 2025 | Updated: April 1st 2025
Tattoo Ink Risks, MultiFrax Laser, and the Impact of GLP-1 Medications on Skin Health
Insights From the ADORING 3 Study and Tapinarof’s Treatment-Free Periods in AD
Published: March 8th 2025 | Updated: April 1st 2025
Insights From the ADORING 3 Study and Tapinarof’s Treatment-Free Periods in AD
Late-Breaking Data: Phase 3 Updates on Ruxolitinib Cream for Prurigo Nodularis
Published: March 8th 2025 | Updated: April 1st 2025
Late-Breaking Data: Phase 3 Updates on Ruxolitinib Cream for Prurigo Nodularis
© 2025 MJH Life Sciences

All rights reserved.